imtesty - As mentioned earlier I am not a scientist. When scanning through the first 20 pages or so of the Cell report a couple of days ago, it seemed to me that lung damage came from other pan BET inhibitors but got no worse for the mice that had been engineered with ACE2 on APB. Did I miss something there?

Regarding your previous post and the trial design. Certainly your comments are valid on one level however a long COVID study would be more worthwhile after it is known if APB actually works to dampin the effects of COVID to begin with. Read that as at least having the potential of sales in the earliest possible time frame. Secondly and probably more likely is that we own shares of an underfunded little biotech company. A long COVID trial would take much more time and money to run, something we don't appear to have at this time.

There was dancing in the street outside my office window the other day when MRK announce that their pill was only 30% effective versus the 50% that was previously reported. That opened the door for APB to have at least have a better chance of one day being on the COVID battle arsenal list.

All IMO, do your own DD

tada